THRIVERecruiting nowVaricose veins; Venous thromboembolism (VTE)THRomboprophylaxis in Individuals undergoing superficial endoVEnouos treatment (THRIVE): a multicentre assessor-blind randomised controlled trial
Recruitment
0 of 3175
Participants
3175
target
Sites
40
NHS
Age
18+
years
Status
Recruiting
EudraCT: 2023-000217-40; IRAS: 1007271; Sponsor reference: 22CX7510
Overview
About this trial
THRIVE is a multi-centre, assessor-blind, randomised controlled trial with a superiority comparison designed to establish whether pharmacological thromboprophylaxis (single dose or extended course) reduces the risk of venous thromboembolism (VTE) in adults undergoing endovenous varicose vein procedures under local anaesthesia, and whether such prophylaxis is cost-effective. Participants are randomised 1:1:1 to compression alone, compression plus a single dose of LMWH, or compression plus a single dose of LMWH followed by an extended course of LMWH or DOAC. The primary outcome is imaging-confirmed lower limb DVT with or without symptoms, or symptomatic PE within 90 days of treatment.
Why this trial is needed
There is currently no high-quality evidence to support pharmacological thromboprophylaxis strategies for patients undergoing endovenous treatments for varicose veins. Practice varies widely, with some clinicians prescribing a single dose of LMWH, others an extended course, and others no pharmacological prophylaxis at all. Existing guidelines reflect this uncertainty. Although a possible treatment effect is suggested by observational data, this evidence is biased by study design and confounding by indication, and grade A evidence is needed to support or refute current practice.
Outcomes
What the trial measures
Primary outcome
Imaging confirmed lower limb DVT with or without symptoms, or PE with symptoms within 90 days of varicose vein treatment
Secondary outcomes
- Individual components of the composite outcome (lower limb DVT with or without symptoms
- PE with symptoms)
- Comparisons of quality of life at 7- and 90-days post-procedure using the EQ-5D
- Mortality rates in each group
- Cost-effectiveness of providing pharmacological thromboprophylaxis (ICER)
- Exploratory analyses to assess how well the DHRA tool and Caprini score predict outcomes
Eligibility
Who can take part
Can take part if
- Adults (>18 years)
- Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia
- Treatment technologies including radiofrequency, laser, mechanochemical foam sclerotherapy and cyanoacrylate glue
Cannot take part if
- Clinical indication for therapeutic anticoagulation e.g. atrial fibrillation
- Previous personal or first-degree relative history of VTE
- Thrombophilia
- Female patients of childbearing potential who have a positive pregnancy test
- A history of allergy to heparins or direct oral anticoagulants
- A history of heparin-induced thrombocytopenia
- Inherited and acquired bleeding disorders
- Evidence of active bleeding
- Concomitant major health problems such as active cancer and chronic renal and/or liver impairment
- Known thrombocytopenia (platelets known to be less than 50 x 10^9/l)
- Major trauma or non-venous surgery that required local risk assessment for VTE in the previous 90 days
- Recent ischemic stroke in the previous 90 days
- Inability to provide consent
Participation
What taking part involves
Intervention
- Arm 1: Compression alone (control)
- Arm 2: Compression plus single dose of low-molecular weight heparin (LMWH) at time of procedure
- Arm 3: Compression plus single dose of LMWH at time of procedure plus extended prophylactic dose of anticoagulation with LMWH or Direct-Acting Oral Anticoagulant (DOAC) for 7, 10 or 14 days
Procedures
- Endovenous intervention of truncal varicose veins under local anaesthesia (radiofrequency, laser, mechanochemical foam sclerotherapy, or cyanoacrylate glue)
- 1:1:1 web-based randomisation stratified by site
- Administration of LMWH (dalteparin sodium, tinzaparin sodium, or enoxaparin sodium) and/or DOAC (rivaroxaban, apixaban, or dabigatran etexilate) according to allocation
- Compression (bandaging, stockings or wraps) for all participants as per local standard of care
- Bilateral lower limb venous duplex ultrasound scan at 21-28 days post-procedure
- EQ-5D quality of life questionnaire at baseline, 7 days, and 90 days
- VTE outcome questionnaire at 7 days and 90 days
- DHRA tool and Caprini risk assessment score at baseline
- Urine pregnancy test pre-procedure for women of childbearing potential randomised to extended pharmacological thromboprophylaxis arm receiving a DOAC
Visit schedule
- Day 0 (day of procedure): baseline assessment, randomisation, intervention administration
- Day 7 post-procedure: central follow-up by telephone or online survey (VTE outcome, EQ-5D, adverse events)
- Day 21-28 post-procedure: bilateral lower limb venous duplex ultrasound scan from groin to ankle conducted locally
- Day 90 post-procedure: central follow-up by telephone or online survey (VTE outcome, EQ-5D, adverse events, compliance, resource use, mortality)
Support
Funding
National Institute for Health Research (NIHR) Health Technology Assessment programme (NIHR152877)